200 Clarendon Street
Boston, Massachusetts 02116
Tel: +1.617.948.6000 Fax: +1.617.948.6001
FIRM / AFFILIATE OFFICES
September 6, 2019
VIA EDGAR AND OVERNIGHT DELIVERY
Division of Corporation Finance
Office of Healthcare & Insurance
United States Securities and Exchange Commission
100 F Street, N.E.
Mail Stop 4720
Washington, D.C. 20549
Attn: Donald Field
Frequency Therapeutics, Inc.
Draft Registration Statement on Form S-1
Submitted August 22, 2019
Dear Mr. Field:
On behalf of Frequency Therapeutics, Inc., a Delaware corporation (the Company), we are transmitting this letter in response to comments received from the staff (the Staff) of the Securities and Exchange Commission by letter dated September 4, 2019 with respect to the Companys confidential Draft Registration Statement on Form S-1 submitted on August 22, 2019 (the Draft Registration Statement). This letter is being submitted together with the Companys Registration Statement on Form S-1 (the Registration Statement), which has been revised to address various of the Staffs comments. The bold and numbered paragraphs below correspond to the numbered paragraphs in the Staffs letter and are followed by the Companys responses. For the Staffs convenience, we are also sending, by courier, copies of this letter and marked copies of the Registration Statement that reflect changes made to the Draft Registration Statement.
September 6, 2019
Impact and prevalence of hearing, page 99
We note your response to comment 4. Please revise the exhibit index to indicate that you will file a consent from Health Advances LLC pursuant to Rule 436 of the Securities Act. For guidance, please refer to Question 233.02 of our Securities Act Rules Compliance and Disclosure Interpretations, which are available on our website.
Response: The Company respectfully acknowledges the Staffs comment and advises the Staff that the consent from Health Advances LLC has been filed as Exhibit 23.3 to the Registration Statement.
Unaudited Consolidated Financial Statements as of June 30, 2018 and 2019
Consolidated Balance Sheets, page F-31
Please revise to reflect only the conversion of preferred stock existing at the latest balance sheet date in the pro forma information presented on the face of your historical financial statements. In this regard, while we do not object to the inclusion of other pro forma adjustments on your capitalization table, we believe that the pro forma presentation on the face of the historical statements should be limited to the impact of pro forma adjustments on financial instruments actually outstanding at the balance sheet date.
Response: The Company respectfully acknowledges the Staffs comment and advises the Staff that it has revised pages F-31 and F-36 in response to the Staffs comment.
Please do not hesitate to contact me at 212-906-2916 or Jennifer Yoon at 617-880-4540 with any questions or further comments you may have regarding this filing or if you wish to discuss the Companys responses above.
|/s/ Nathan Ajiashvili|
of LATHAM & WATKINS LLP
David L. Lucchino, Frequency Therapeutics, Inc.
Michael D. Bookman, Frequency Therapeutics, Inc.
Jennifer A. Yoon, Latham & Watkins LLP
Arthur D. Robinson, Simpson Thacher & Bartlett LLP